Combination of Sulindac and Metformin as a Therapeutic Target in Lung Cancer

Author

• Heather Butler

Date of Award

2020

Document Type

Dissertation/Thesis

Submission Date

October 2026

Thesis/Dissertation Advisor [Chair]

Trivigno, Catherine

Abstract

Sulindac is an FDA approved, non-steroidal anti-inflammatory drug that exhibits anti-cancer properties. Metformin is and FDA approved, anti-diabetic drug that also has documented anti-cancer properties. The goal of this project was to explore if a dual-combination of sulindac and metformin in the presence of a chemical oxidizing agent is more effective in killing lung cancer cells while not inducing cell death in normal lung cells. Our data shows that a triple-drug combination of sulindac, metformin, and tert-butyl hydroperoxide induce significant cell death in lung cancer cells but did not induce significant cell death in normal lung cells.

Comments

Includes bibliography.

Recommended Citation

Butler, Heather, "Combination of Sulindac and Metformin as a Therapeutic Target in Lung Cancer" (2020). Harriet L Wilkes Honors College Theses 2010 - 2019. 473.
https://digitalcommons.fau.edu/etd_honors_2/473

Extent

32 p.

Identifier

FA00003700